Latest NAV & returns of NIPPON INDIA PRIVATE LTD.

Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl

Add To Compare

previously known as Nippon India Pharma Dir DR until

NAV on February 06, 2023
Category Equity:
Sector - Healthcare
Investment StyleBox
Large Growth
Total Assets 4,422 cr
Turnover Ratio 38.42%
Expense Ratio 1.11%
Exit Load 1.00%if redeemed within
1 Months
0.00%if redeemed after 1 Months
Returns
  • 1M: -2.86%
  • 1Y: -2.19%
  • 3M: -6.63%
  • 3Y: 24.41%
  • 6M: -1.36%
  • 5Y: 17.62%
Min Investment 5,000
ADDITIONAL INFO
Fund Manager Sailesh Raj Bhan (Since almost 18 years) Kinjal Desai (Since over 4 years) Akshay Sharma (Since 2 months)
ISIN INF204K01I43
Fund Family Nippon India
P/E Ratio 32.86
P/B Ratio 4.01
Launch Date January 01, 2013
Benchmark S&P BSE Healthcare TR INR
ASSET ALLOCATION
EQUITY DISTRIBUTION
RISK MEASURES (3 yrs)
vs S&P BSE Healthcare TR INR

Alpha 7.05
Beta 0.93
R-Squared 95.52
Info Ratio 1.55
Tracking Err 4.80
Sortino 2.141
Sharpe 0.972
Std Dev 21.260
Risk -
SECTOR WEIGHTINGS (%)
Financial 0.0%
Industrial 0.0%
Technology 0.0%
Basic Materials 0.0%
Consumer Cyclical 0.0%
Utilities Services 0.0%
Healthcare Services 100.00%
Energy Services 0.00%
Communication Services 0.00%
Consumer Defensive 0.00%
Real Estate 0.00%
INVESTMENT OBJECTIVE

The Fund seeks to invest in pharma sector with focus on important segments of the sector viz Domestic Business, International & CRAMS and include deep value as well as high growth pharma businesses. The fund invests across market capitalization within the sector. It may suit investment horizon of around 2-3 years.

Dividends that would otherwise be paid out to investors are instead used to purchase more units in the fund. Not as tax efficient as Growth.

View Factsheet

-
Best Sector Healthcare Funds
NAME LATEST
NAV
RETURNS
1y    
FUND
ASSETS
Expense
RATIO
RISK
243.302 -1.46% 1,736 cr 1.08% -


Other plans of Nippon India Pharma


Other Equity funds by Nippon India